What drug is dabrafenib? What is its mechanism of action

Dabrafenib is an oral targeted anticancer drug, mainly classified as a BRAF kinase inhibitor, and is used to treat advanced or metastatic malignant tumors with BRAF V600E or V600K mutations. Such gene mutations can lead to abnormal activation of BRAF protein, thereby continuously stimulating the MAPK/ERK pathway and promoting the growth and spread of tumor cells. The mechanism of action of dabrafenib is to precisely inhibit mutant BRAF kinase, thereby interrupting this signaling pathway and slowing or blocking the proliferation of cancer cells.

BRAF gene mutations have been found in a variety of tumors, especially melanoma, non-small cell lung cancer, thyroid cancer, and brain glioblastoma. As a second-generation BRAF inhibitor, dabrafenib was originally developed to make up for the short-term efficacy of previous targeted therapies due to resistance. In inhibiting BRAF V600E kinase, dabrafenib shows greater selectivity and higher bioavailability than the first-generation drug, while achieving certain optimization in safety and efficacy.

It is worth noting that although dabrafenib alone can effectively delay the growth of cancer cells, due to feedback activation of the MEK pathway after BRAF inhibition, it often needs to be used in combination with MEK inhibitors such as trametinib to achieve double blockade and further delay the emergence of drug resistance. International guidelines have included dabrafenib combination therapy as one of the important treatment strategies for advanced BRAF mutant tumors.

In terms of mechanism, after being orally absorbed, dabrafenib rapidly distributes to the blood and tumor tissues, selectively binds toBRAF V600 mutant kinase, inhibits its activity, and ultimately inhibits ERK signal conduction and related gene expression. In addition, dabrafenib also has a slight effect on some possible side targets, such as C-RAF, SRMS, etc., but these inhibitory activities are much lower than the affinity for BRAF.

In summary, dabrafenib represents a new paradigm in tumor treatment in the era of precision medicine. By identifying and targeting tumor core driver gene mutations, it improves treatment selectivity while reducing damage to normal cells.

Reference materials:https://go.drugbank.com/drugs/DB08912